Sanofi



Sanofi

Lixisenatide was invented by Zealand Pharma and global rights are licensed by Sanofi (SAN.PA). Lyxumia® is the intended trademark for lixisenatide. Lixisenatide is not currently approved or licensed anywhere in the world.

There are two programs being developed through the partnership with sanofi. The most advanced program, which involves the use of lixisenatide as a monotherapy, is in late Phase III testing and has reported encouraging initial Phase III results. The second most advanced program involves a combination of lixisenatide and Sanofi's Lantus® (insulin glargine), a once-daily, long-acting insulin analog; a complete Phase III developent program is being finalized, and initial Phase III clinical trial results for lixisenatide administered in "free combination" with Lantus® were announced in September 2010.

To top of page

Tip a friend

Fill in the form below to tip a friend about this page.






Subscribe

When this page is updated you will be updated by e-mail.



Related links